Loading...
XTAEBWAY
Market cap175mUSD
Dec 24, Last price  
1,703.00ILS
Name

Brainsway Ltd

Chart & Performance

D1W1MN
XTAE:BWAY chart
P/E
—
P/S
553.49
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
14.78%
Rev. gr., 5y
14.15%
Revenues
32m
+16.96%
364,2491,189,0003,380,0006,800,00011,524,00011,145,00016,397,00023,101,00022,057,00029,657,00027,177,00031,785,000
Net income
-4m
L-68.56%
-5,916,383-7,122,000-6,545,000-4,087,000-2,397,000-7,054,000-6,479,000-10,328,000-5,385,000-6,462,000-13,349,000-4,197,000
CFO
1m
P
-5,603,556-2,363,000-3,793,000-4,552,000-2,402,000-3,467,000-3,773,000-7,244,000-1,436,000884,000-9,759,0001,284,000
Earnings
Mar 04, 2025

Profile

Brainsway Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, Europe, Israel, and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company primarily serves doctors, hospitals, and medical centers in the field of psychiatry. Brainsway Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.
URL
https://www.brainsway.com/
IPO date
Dec 24, 2006
Employees
134
Domiciled in
IL
Incorporated in
IL

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
31,785
16.96%
27,177
-8.36%
29,657
34.46%
Cost of revenue
36,604
39,860
34,656
Unusual Expense (Income)
NOPBT
(4,819)
(12,683)
(4,999)
NOPBT Margin
Operating Taxes
251
315
43
Tax Rate
NOPAT
(5,070)
(12,998)
(5,042)
Net income
(4,197)
-68.56%
(13,349)
106.58%
(6,462)
20.00%
Dividends
Dividend yield
Proceeds from repurchase of equity
(52)
42,260
BB yield
0.09%
-22.44%
Debt
Debt current
232
234
500
Long-term debt
710
742
1,008
Deferred revenue
5,314
4,669
3,419
Other long-term liabilities
6,077
6,016
5,921
Net debt
(45,043)
(46,876)
(55,841)
Cash flow
Cash from operating activities
1,284
(9,759)
884
CAPEX
(2,387)
1,936
(2,238)
Cash from investing activities
(37,409)
42,169
(42,216)
Cash from financing activities
(1,026)
(1,547)
41,516
FCF
(3,639)
(11,343)
(4,078)
Balance
Cash
45,985
47,852
57,349
Long term investments
Excess cash
44,396
46,493
55,866
Stockholders' equity
(98,763)
(98,929)
(85,582)
Invested Capital
152,206
155,499
152,982
ROIC
ROCE
EV
Common stock shares outstanding
16,578
15,386
15,577
Price
11.49
222.48%
3.56
-70.53%
12.09
5.87%
Market cap
190,479
247.47%
54,819
-70.89%
188,327
47.00%
EV
145,436
7,943
132,486
EBITDA
(3,482)
(11,148)
(3,313)
EV/EBITDA
Interest
48
46
1,420
Interest/NOPBT